This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amit, T. Articles by Hochberg, Z.'e. Search for Related Content PubMed PubMed Citation Articles by Amit, T. Articles by Hochberg, Z.'e.

Does Serum Growth Hormone (GH) Binding Protein Reflect Human GH Receptor Function?

Department of Pharmacology, Bruce Rappaport Faculty of Medicine, Technion, and Rambam Medical Center, Haifa 31096, Israel

Address correspondence and requests for reprints to: Dr. Ze’ev Hochberg, Rambam Medical Center, POB 9602, Haifa 31096, Israel. E-mail: Z.HOCHBERG{at}RAMBAM.HEALTH.GOV.IL

Previous observations raised the possibility that circulating GH-binding protein (GHBP) may serve as a useful index for tissue GH receptor (GHR) responsiveness in humans. Indeed, there are many examples to indicate that across a wide scope of comparative studies, ontogenic data, experimental systems, physiological conditions, nutritional states, and diseases there is a close relationship between the concentration of GHR and the level of serum GHBP. In the present review, we discuss various aspects that might affect differentially cellular GHR and circulating GHBP, based on species and tissue divergence, regulation of cell-surface GHR turnover, GHR cleavage mechanism, GHR mRNA splicing, and GH insensitivity (GHI) syndrome patients with normal or high serum GHBP levels. Most previous experimental data were collected through comparative analysis of human GHBP against GHR and GHBP determinations in animal models. Yet, GHBPs possess species-specific properties, and the mechanism for their generation and regulation display evolutionary divergence. Another important aspect is tissue divergence, in terms of GHR regulation and its cleavage to GHBP. Although GHBP is generated mainly from the liver GHR, many other tissues express GHRs and probably also contribute to the total GHBP level. Human GHBP is generated by proteolytic cleavage of GHR at the cell-surface and, thus, occupancy or modulation of GHR turnover/internalization would impact the level of cell-surface GHR that are available for proteolysis. An additional degree of complexity arises from recent reports, implicating a protein kinase C-regulated metalloprotease activity in GHBP generation. This suggests that the proteolytic system, which controls the specific cleavage mechanism and switch between GHR proteolysis and GHBP shedding, is a regulated process. Finally, differential splicing regulation to the full-length, active human GHR (hGHR) and the inactive truncated hGHRtr isoform messenger RNA transcripts might regulate both the production of GHBP and GHR bioactivity, as hGHRtr generates large amounts of GHBP but has a dominant negative effect on GH signaling. Several clinical GH-resistant conditions, such as liver cirrhosis, renal insufficiency, insulin-dependent diabetes mellitus, hypothyroidism, malnutrition, or critical illness are associated with reduced GHBP levels. However, this is not universally true, as in other conditions (e.g. early childhood, acromegaly) decreased GHBP levels are not associated with GHI. Divergence between serum GHBP and insulin-like growth factor I, such as which occur during puberty or obesity, also questions whether GHBP levels reflect GHR function. Even in patients with GHI syndrome, serum GHBP cannot be relied on to detect all GHR mutations.

The correct assessment of GHR expression and GH functionality in an individual patient will require, in parallel to measurements of serum GHBP, additional detailed diagnostic screening of the entire GH-insulin-like growth factor I axis.

This article has been cited by other articles:

				K. Pazaitou-Panayiotou, T. Kelesidis, I. Kelesidis, A. Kaprara, J. Blakeman, I. Vainas, A. Mpousoulegas, C. J Williams, and C. Mantzoros Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer Eur. J. Endocrinol., February 1, 2007; 156(2): 187 - 194. [Abstract] [Full Text] [PDF]

				J. Fuglsang, P. Sandager, N. Moller, S. Fisker, H. Orskov, and P. Ovesen Kinetics and secretion of placental growth hormone around parturition. Eur. J. Endocrinol., March 1, 2006; 154(3): 449 - 457. [Abstract] [Full Text] [PDF]

				R. A. Feelders, M. Bidlingmaier, C. J. Strasburger, J. A. M. J. L. Janssen, P. Uitterlinden, L. J. Hofland, S. W. J. Lamberts, A. J. van der Lely, and W. W. de Herder Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6480 - 6489. [Abstract] [Full Text] [PDF]

				D. Mesotten, P. J. Wouters, R. P. Peeters, K. V. Hardman, J. M. Holly, R. C. Baxter, and G. Van den Berghe Regulation of the Somatotropic Axis by Intensive Insulin Therapy during Protracted Critical Illness J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3105 - 3113. [Abstract] [Full Text] [PDF]

				E. M. Kofoed, V. Hwa, B. Little, K. A. Woods, C. K. Buckway, J. Tsubaki, K. L. Pratt, L. Bezrodnik, H. Jasper, A. Tepper, et al. Growth Hormone Insensitivity Associated with a STAT5b Mutation N. Engl. J. Med., September 18, 2003; 349(12): 1139 - 1147. [Full Text] [PDF]

				M. Lampit and Z.'e. Hochberg Prevention of Growth Deceleration after Withdrawal of Growth Hormone Therapy in Idiopathic Short Stature J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3573 - 3577. [Abstract] [Full Text] [PDF]

				R. Coutant, F. Boux de Casson, S. Rouleau, O. Douay, E. Mathieu, M. Audran, and J. M. Limal Body Composition, Fasting Leptin, and Sex Steroid Administration Determine GH Sensitivity in Peripubertal Short Children J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5805 - 5812. [Abstract] [Full Text] [PDF]

				A. Eliakim, T. P. Scheett, R. Newcomb, S. Mohan, and D. M. Cooper Fitness, Training, and the Growth Hormone{->}Insulin-Like Growth Factor I Axis in Prepubertal Girls J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2797 - 2802. [Abstract] [Full Text] [PDF]

				M. Bondanelli, A. Margutti, M. R. Ambrosio, L. Plaino, L. Cobellis, F. Petraglia, and E. C. degli Uberti Blood Growth Hormone-Binding Protein Levels in Premenopausal and Postmenopausal Women: Roles of Body Weight and Estrogen Levels J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1973 - 1980. [Abstract] [Full Text]

				Y. Zhang, R. Guan, J. Jiang, J. J. Kopchick, R. A. Black, G. Baumann, and S. J. Frank Growth Hormone (GH)-induced Dimerization Inhibits Phorbol Ester-stimulated GH Receptor Proteolysis J. Biol. Chem., June 29, 2001; 276(27): 24565 - 24573. [Abstract] [Full Text] [PDF]